|
1
|
Bandarchi B, Ma L, Navab R, Seth A and
Rasty G: From melanocyte to metastatic malignant melanoma. Dermatol
Res Pract. 2010:5837482010.PubMed/NCBI
|
|
2
|
Ferlay J, Steliarova-Foucher E,
Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D and
Bray F: Cancer incidence and mortality patterns in Europe:
Estimates for 40 countries in 2012. Eur J Cancer. 49:1374–1403.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Erdmann F, Lortet-Tieulent J, Schüz J,
Zeeb H, Greinert R, Breitbart EW and Bray F: International trends
in the incidence of malignant melanoma 1953–2008 - are recent
generations at higher or lower risk? Int J Cancer. 132:385–400.
2013. View Article : Google Scholar
|
|
4
|
Kesmodel SB and Spitz FR: Gene therapy for
cancer and metastatic disease. Expert Rev Mol Med. 5:1–18. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bhatia S, Tykodi SS and Thompson JA:
Treatment of metastatic melanoma: An overview. Oncology (Williston
Park). 23:488–496. 2009.
|
|
6
|
Moon DO, Kang CH, Kim MO, Jeon YJ, Lee JD,
Choi YH and Kim GY: Beta-lapachone (LAPA) decreases cell viability
and telomerase activity in leukemia cells: Suppression of
telomerase activity by LAPA. J Med Food. 13:481–488. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Guiraud P, Steiman R, Campos-Takaki GM,
Seigle-Murandi F and Simeon de Buochberg M: Comparison of
antibacterial and antifungal activities of lapachol and
beta-lapachone. Planta Med. 60:373–374. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
de Almeida ER, da Silva Filho AA, dos
Santos ER and Lopes CA: Antiinflammatory action of lapachol. J
Ethnopharmacol. 29:239–241. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li CJ, Zhang LJ, Dezube BJ, Crumpacker CS
and Pardee AB: Three inhibitors of type 1 human immunodeficiency
virus long terminal repeat-directed gene expression and virus
replication. Proc Natl Acad Sci USA. 90:1839–1842. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Planchon SM, Wuerzberger S, Frydman B,
Witiak DT, Hutson P, Church DR, Wilding G and Boothman DA:
Beta-lapachone-mediated apoptosis in human promyelocytic leukemia
(HL-60) and human prostate cancer cells: A p53-independent
response. Cancer Res. 55:3706–3711. 1995.PubMed/NCBI
|
|
11
|
Planchon SM, Pink JJ, Tagliarino C,
Bornmann WG, Varnes ME and Boothman DA: Beta-lapachone-induced
apoptosis in human prostate cancer cells: Involvement of NQO1/xip3.
Exp Cell Res. 267:95–106. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Müller K, Sellmer A and Wiegrebe W:
Potential antipsoriatic agents: Lapacho compounds as potent
inhibitors of HaCaT cell growth. J Nat Prod. 62:1134–1136. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sitônio MM, Carvalho Júnior CH, Campos IA,
Silva JB, Lima MC, Góes AJ, Maia MB, Rolim Neto PJ and Silva TG:
Anti-inflammatory and anti-arthritic activities of
3,4-dihydro-2,2-dimethyl-2H-naphthol[1,2-b]pyran-5,6-dione
(β-lapachone). Inflamm Res. 62:107–113. 2013. View Article : Google Scholar
|
|
14
|
Frydman B, Marton LJ, Sun JS, Neder K,
Witiak DT, Liu AA, Wang HM, Mao Y, Wu HY, Sanders MM, et al:
Induction of DNA topoisomerase II-mediated DNA cleavage by
beta-lapachone and related naphthoquinones. Cancer Res. 57:620–627.
1997.PubMed/NCBI
|
|
15
|
Chau YP, Shiah SG, Don MJ and Kuo ML:
Involvement of hydrogen peroxide in topoisomerase inhibitor
beta-lapachone-induced apoptosis and differentiation in human
leukemia cells. Free Radic Biol Med. 24:660–670. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shiah SG, Chuang SE, Chau YP, Shen SC and
Kuo ML: Activation of c-Jun NH2-terminal kinase and subsequent
CPP32/Yama during topoisomerase inhibitor beta-lapachone-induced
apoptosis through an oxidation-dependent pathway. Cancer Res.
59:391–398. 1999.PubMed/NCBI
|
|
17
|
Choi YH, Kang HS and Yoo MA: Suppression
of human prostate cancer cell growth by beta-lapachone via
down-regulation of pRB phosphorylation and induction of Cdk
inhibitor p21(WAF1/CIP1). J Biochem Mol Biol. 36:223–229. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pink JJ, Wuerzberger-Davis S, Tagliarino
C, Planchon SM, Yang X, Froelich CJ and Boothman DA: Activation of
a cysteine protease in MCF-7 and T47D breast cancer cells during
beta-lapachone-mediated apoptosis. Exp Cell Res. 255:144–155. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wuerzberger SM, Pink JJ, Planchon SM,
Byers KL, Bornmann WG and Boothman DA: Induction of apoptosis in
MCF-7:WS8 breast cancer cells by beta-lapachone. Cancer Res.
58:1876–1885. 1998.PubMed/NCBI
|
|
20
|
Dong GZ, Oh ET, Lee H, Park MT, Song CW
and Park HJ: Beta-lapachone suppresses radiation-induced activation
of nuclear factor-kappaB. Exp Mol Med. 42:327–334. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yu HY, Kim SO, Jin CY, Kim GY, Kim WJ, Yoo
YH and Choi YH: β-lapachone-induced apoptosis of human gastric
carcinoma AGS cells is caspase-dependent and regulated by the
PI3K/Akt pathway. Biomol Ther (Seoul). 22:184–192. 2014. View Article : Google Scholar
|
|
22
|
Wierstra I: Sp1: Emerging roles - beyond
constitutive activation of TATA-less housekeeping genes. Biochem
Biophys Res Commun. 372:1–13. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Black AR, Black JD and Azizkhan-Clifford
J: Sp1 and krüppel-like factor family of transcription factors in
cell growth regulation and cancer. J Cell Physiol. 188:143–160.
2001. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kong LM, Liao CG, Fei F, Guo X, Xing JL
and Chen ZN: Transcription factor Sp1 regulates expression of
cancer-associated molecule CD147 in human lung cancer. Cancer Sci.
101:1463–1470. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sankpal UT, Goodison S, Abdelrahim M and
Basha R: Targeting Sp1 transcription factors in prostate cancer
therapy. Med Chem. 7:518–525. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jiang Y, Wang L, Gong W, Wei D, Le X, Yao
J, Ajani J, Abbruzzese JL, Huang S and Xie K: A high expression
level of insulin-like growth factor I receptor is associated with
increased expression of transcription factor Sp1 and regional lymph
node metastasis of human gastric cancer. Clin Exp Metastasis.
21:755–764. 2004. View Article : Google Scholar
|
|
27
|
Kim DW, Ko SM, Jeon YJ, Noh YW, Choi NJ,
Cho SD, Moon HS, Cho YS, Shin JC, Park SM, et al:
Anti-proliferative effect of honokiol in oral squamous cancer
through the regulation of specificity protein 1. Int J Oncol.
43:1103–1110. 2013.PubMed/NCBI
|
|
28
|
Zhang R, Luo H, Wang S, Chen W, Chen Z,
Wang HW, Chen Y, Yang J, Zhang X, Wu W, et al: MicroRNA-377
inhibited proliferation and invasion of human glioblastoma cells by
directly targeting specificity protein 1. Neuro Oncol.
16:1510–1522. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Abdelrahim M, Smith R III, Burghardt R and
Safe S: Role of Sp proteins in regulation of vascular endothelial
growth factor expression and proliferation of pancreatic cancer
cells. Cancer Res. 64:6740–6749. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shin JA, Han G, Kim HJ, Kim HM and Cho SD:
Chemopreventive and chemotherapeutic effect of a novel histone
deacetylase inhibitor, by specificity protein 1 in MDA-MB-231 human
breast cancer cells. Eur J Cancer Prev. 23:277–285. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cho JH, Shin JC, Cho JJ, Choi YH, Shim JH
and Chae JI: Esculetin (6,7-dihydroxycoumarin): A potential cancer
chemo-preventive agent through suppression of Sp1 in oral squamous
cancer cells. Int J Oncol. 46:265–271. 2015.
|
|
32
|
Safdie FM, Dorff T, Quinn D, Fontana L,
Wei M, Lee C, Cohen P and Longo VD: Fasting and cancer treatment in
humans: A case series report. Aging (Albany NY). 1:988–1007.
2009.
|
|
33
|
Wilson RM and Danishefsky SJ: Small
molecule natural products in the discovery of therapeutic agents:
The synthesis connection. J Org Chem. 71:8329–8351. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tobin DD, Menon M, Menon M, Spatta BC,
Hodges EV and Perry DG: The intrapsychics of gender: A model of
self-socialization. Psychol Rev. 117:601–622. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li CJ, Averboukh L and Pardee AB:
Beta-lapachone, a novel DNA topoisomerase I inhibitor with a mode
of action different from camptothecin. J Biol Chem.
268:22463–22468. 1993.PubMed/NCBI
|
|
36
|
Jackson JK, Higo T, Hunter WL and Burt HM:
Topoisomerase inhibitors as anti-arthritic agents. Inflamm Res.
57:126–134. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Tudan C, Jackson JK, Higo TT and Burt HM:
The effect of inhibiting topoisomerase I and II on the
anti-apoptotic response associated with pro-inflammatory crystals
of calcium pyrophosphate dihydrate in human neutrophils. Inflamm
Res. 52:8–17. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Safe S and Abdelrahim M: Sp transcription
factor family and its role in cancer. Eur J Cancer. 41:2438–2448.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Li L and Davie JR: The role of Sp1 and Sp3
in normal and cancer cell biology. Ann Anat. 192:275–283. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hsu TI, Wang MC, Chen SY, Yeh YM, Su WC,
Chang WC and Hung JJ: Sp1 expression regulates lung tumor
progression. Oncogene. 31:3973–3988. 2012. View Article : Google Scholar :
|
|
41
|
Kavurma MM and Khachigian LM: Sp1 inhibits
proliferation and induces apoptosis in vascular smooth muscle cells
by repressing p21WAF1/Cip1 transcription and cyclin
D1-Cdk4-p21WAF1/Cip1 complex formation. J Biol Chem.
278:32537–32543. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Xu R, Zhang P, Huang J, Ge S, Lu J and
Qian G: Sp1 and Sp3 regulate basal transcription of the survivin
gene. Biochem Biophys Res Commun. 356:286–292. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chae JI, Jeon YJ and Shim JH:
Downregulation of Sp1 is involved in honokiol-induced cell cycle
arrest and apoptosis in human malignant pleural mesothelioma cells.
Oncol Rep. 29:2318–2324. 2013.PubMed/NCBI
|
|
44
|
Hong IK, Byun HJ, Lee J, Jin YJ, Wang SJ,
Jeoung DI, Kim YM and Lee H: The tetraspanin CD81 protein increases
melanoma cell motility by up-regulating metalloproteinase MT1-MMP
expression through the pro-oncogenic Akt-dependent Sp1 activation
signaling pathways. J Biol Chem. 289:15691–15704. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Liu X, Yang WT and Zheng PS: Msi1 promotes
tumor growth and cell proliferation by targeting cell cycle
checkpoint proteins p21, p27 and p53 in cervical carcinomas.
Oncotarget. 5:10870–10885. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Sherr CJ and Roberts JM: CDK inhibitors:
Positive and negative regulators of G1-phase progression. Genes
Dev. 13:1501–1512. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Murray AW: Recycling the cell cycle:
Cyclins revisited. Cell. 116:221–234. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Ewen ME and Lamb J: The activities of
cyclin D1 that drive tumorigenesis. Trends Mol Med. 10:158–162.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Weinstein IB: Relevance of cyclin D1 and
other molecular markers to cancer chemoprevention. J Cell Biochem
Suppl. 25:23–28. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Fu M, Wang C, Li Z, Sakamaki T and Pestell
RG: Minireview: Cyclin D1: normal and abnormal functions.
Endocrinology. 145:5439–5447. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Li F, Ambrosini G, Chu EY, Plescia J,
Tognin S, Marchisio PC and Altieri DC: Control of apoptosis and
mitotic spindle checkpoint by survivin. Nature. 396:580–584. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Jarrin M, Mansergh FC, Boulton ME, Gunhaga
L and Wride MA: Survivin expression is associated with lens
epithelial cell proliferation and fiber cell differentiation. Mol
Vis. 18:2758–2769. 2012.PubMed/NCBI
|
|
53
|
Xu Q, Liu M, Xu N and Zhu H: Variation in
Sp1 binding sites correlates with expression of survivin in breast
cancer. Mol Med Rep. 10:1395–1399. 2014.PubMed/NCBI
|
|
54
|
Grütter MG: Caspases: Key players in
programmed cell death. Curr Opin Struct Biol. 10:649–655. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Porter AG and Jänicke RU: Emerging roles
of caspase-3 in apoptosis. Cell Death Differ. 6:99–104. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Elmore S: Apoptosis: A review of
programmed cell death. Toxicol Pathol. 35:495–516. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Vaziri H, West MD, Allsopp RC, Davison TS,
Wu YS, Arrowsmith CH, Poirier GG and Benchimol S: ATM-dependent
telomere loss in aging human diploid fibroblasts and DNA damage
lead to the post-translational activation of p53 protein involving
poly(ADP-ribose) polymerase. EMBO J. 16:6018–6033. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Zauli G, Gibellini D, Caputo A, Bassini A,
Negrini M, Monne M, Mazzoni M and Capitani S: The human
immunodeficiency virus type-1 Tat protein upregulates Bcl-2 gene
expression in Jurkat T-cell lines and primary peripheral blood
mononuclear cells. Blood. 86:3823–3834. 1995.PubMed/NCBI
|
|
59
|
Yang E, Zha J, Jockel J, Boise LH,
Thompson CB and Korsmeyer SJ: Bad, a heterodimeric partner for
Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell.
80:285–291. 1995. View Article : Google Scholar : PubMed/NCBI
|
